• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Weekly Roundup: April 12-16, 2021

ICYMI, some of this week’s featured content includes new safety data on baricitinib for atopic dermatitis, low malignancy risk for secukinumab in psoriasis, new columns, video coverage from the Inaugural Symposium for Inflammatory Skin Disease, plus more.

POLL: Have you seen a rise in aesthetic procedures at your practice since the pandemic began?

COVID-19 Pandemic Provides Glimpse Into Potential Cause of Kawasaki Disease in Children

Given the high prevalence of Kawasaki disease during the pandemic, Japanese investigators determined that droplet or contact transmission of pathogens is likely not a major route causing the development of the disease.

The Mainstream Patient: April 12, 2021

This week’s edition of The Mainstream Patient features stories on fraxel lasers, microcurrent facials, perioral dermatitis, brow lifts, plus more.

Solving Pierced Earring Challenges

In this month's Cosmetic Conundrums column, Dermatology Times Chief Medical Editor Zoe Diana Draelos, MD, discusses how to solve common challenges associated with pierced earrings.

Study Confirms Safety Profile of Baricitinib Dose for Atopic Dermatitis

Initial rates of common treatment-emergent adverse events from baricitinib 2 mg appear to remain stable or decrease with prolonged exposure.

Malignancy Risk Low in Secukinumab Treatment

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

Tazarotene Excels Across BMI Categories

Data from trials show tazarotene 0.045% lotion is an effective treatment for moderate to severe facial acne and improves acne-related QOL in patients across BMI categories.

Probiotic Strains Have Potential to Prevent Pediatric AD

Some strains appear to reduce risk in pregnant women and infants

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

COVID-19 Vaccine Refusal: Grounds for Termination?

In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores the legality of terminating an employee for refusing a COVID-19 vaccine.

Utilizing Topicals for Atopic Dermatitis

In this video interview, Linda Stein Gold, MD, discusses her recent presentation at the Inaugural SISD regarding using topicals for atopic dermatitis.

Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.